Discovery of 18 F Labeled AZD5213 Derivatives as Novel Positron Emission Tomography (PET) Radioligands Targeting Histamine Subtype‐3 Receptor
ChemBioChem · 2025
DOI: 10.1002/cbic.202400655 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Zhendong Song und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA, 30322, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Fluorine Radioisotopes, Receptors, Histamine H3, Radiopharmaceuticals. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
The histamine subtype 3 (H 3 ) receptor is an important drug target in the central nervous system (CNS), and PET imaging offers a promising technique for the noninvasive evaluation of CNS disease related to the H 3 receptor. In this study, we synthesized and evaluated the binding effects of [ 18 F]H3–2404 and [ 18 F]H3–2405 by modifying the structure of AZD5213, a selective H 3 antagonist. These two radioligands were prepared in high radiochemical yields and displayed stability in serum. The in vitro autoradiographic study in rat brain tissue and the following in vivo PET studies in mice demonstrated sufficient brain uptake but predominantly non‐specific distribution in rodent brain. Although these data suggest that [ 18 F]H3–2404 and [ 18 F]H3–2405 are unsuitable as PET tracers for brain imaging of the H 3 receptor, this study provides a valuable attempt for optimizing 18 F labeled radiotracers based on AZD5213.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, GA, 30322, USA.
- PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
- Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA.
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, 02114, USA.
ORCID-Profile: Zhendong Song, Yinlong Li, Steven H Liang
Zitieren
APA
Song, Z., Li, Y., Dahl, K., Chaudhary, A., Sun, Z., Zhou, X., Chen, J., Gao, Y., Rong, J., Zhao, C., Patel, J. S., Collier, L., Ran, C., Zhai, C., Zhang, L., Haider, A., Mühlfenzl, K. S., Yuan, H., Elmore, C. S., …, & Liang, S. H. (2025). Discovery of 18 F Labeled AZD5213 Derivatives as Novel Positron Emission Tomography (PET) Radioligands Targeting Histamine Subtype‐3 Receptor. ChemBioChem. https://doi.org/10.1002/cbic.202400655
Vancouver
Song Z, Li Y, Dahl K, Chaudhary A, Sun Z, Zhou X, et al. Discovery of 18 F Labeled AZD5213 Derivatives as Novel Positron Emission Tomography (PET) Radioligands Targeting Histamine Subtype‐3 Receptor. ChemBioChem. 2025. doi:10.1002/cbic.202400655
BibTeX
@article{Song2025,
author = {Song, Zhendong and Li, Yinlong and Dahl, Kenneth and Chaudhary, Ahmad and Sun, Zhenkun and Zhou, Xin and Chen, Jiahui and Gao, Yabiao and Rong, Jian and Zhao, Chunyu and Patel, Jimmy S and Collier, Lee and Ran, Chongzhao and Zhai, Chuangyan and Zhang, Linqi and Haider, Achi and Mühlfenzl, Kim S and Yuan, Hongjie and Elmore, Charles S and Schou, Magnus and Liang, Steven H},
title = {Discovery of 18 F Labeled AZD5213 Derivatives as Novel Positron Emission Tomography (PET) Radioligands Targeting Histamine Subtype‐3 Receptor},
journal = {ChemBioChem},
year = {2025},
doi = {10.1002/cbic.202400655}
}
EUVIMED